@MaxReichertMD

Professorship for Translational Pancreatic Cancer Research, Board of Directors - Center for Organoid Systems (COS), Attending Physician in GI & GI Oncology, TUM

 Munich, Bavaria
Joined November 2018
  • Tweets195
  • Following341
  • Followers672
6Media
There is an opening for a postdoc in my laboratory. The aim of the post is to develop and use novel methodologies for mass spectrometry and phosphoproteomics analysis in complex multicellular environments. cruk.manchester.ac.uk/career…

MI/26/52 Postdoctoral Scientist | Cancer Research UK Manchester Institute

Dr Claus Jorgensen, Group Leader of the Systems Oncology Group, is looking for a Postdoctoral Scientist to join his group. This is a great opportunity for a self-motivated, innovative, meticulous and...

cruk.manchester.ac.uk
8
6
613
Maximilian Reichert retweeted
TU München@TU_MuenchenOct 15
How can lab-grown models deepen our understanding of the human body? Our latest TUM #ScienceGlossary introduces #organoids and artificial tissues and their potential for #biomedical research and #healthcare: go.tum.de/219479 #FutureOfMedicine 📷TUM CCC / M. Hebrok
Orange TUM Science Glossary card titled “Organoids and artificial tissue.” It explains that organoids are lab-grown miniature organ-like structures and artificial tissues are engineered human tissues. They can be used to study diseases, test treatments, develop curative stem cell therapies, provide more realistic disease models and help reduce animal testing.

ALT Orange TUM Science Glossary card titled “Organoids and artificial tissue.” It explains that organoids are lab-grown miniature organ-like structures and artificial tissues are engineered human tissues. They can be used to study diseases, test treatments, develop curative stem cell therapies, provide more realistic disease models and help reduce animal testing.

3
8
1,034
So happy we’ve opened the Center for Organoid Systems (COS) at @TU_Muenchen! Together, we want to build connected organoid systems—recreating how disease in one tissue affects another, and testing new ways to intervene. #organoids #PancreaticCancer @DKTK_ @BZKF_bayern
2
3
13
346
Especially grateful to Thomas Hofmann and @TU_Muenchen, and to @MarkusBlume and the #HightechAgendaBayern for their support.
1
3
98
Really excited to work with our fantastic colleagues in the years ahead. Can’t wait to see what we’ll discover together! @HebrokLab @BauschLab @grunewaju @SimonTSchafer @schirmer_lab @LabWolfrum @LabReichert Anna Dowbaj & Alessandra Moretti
4
80
Maximilian Reichert retweeted
Chiara Falcomatà@ChiaraFalcomataSep 9
Pancreatic tumors are highly heterogeneous and immunosuppressive. But is immune resistance imposed across the whole tumor - or built locally by distinct cancer-cell states? I’m incredibly excited to share our new paper, now out in @Nature! 🎉 doi.org/10.1038/s41586-026-1… (1/7)

A serpin–myeloid axis in pancreatic cancer heterogeneity and immune evasion

Nature - SERPINE1 and SERPINB2-driven fibrin-rich niches locally programme immunosuppressive macrophages and exclude T cells, enabling spatially organized immune evasion in pancreatic ductal...

nature.com
10
71
6
338
34,722
Maximilian Reichert retweeted
Anirban Maitra@Aiims1742Jul 8
EMA fast tracks review of a medicine for metastatic #PancreaticCancer The medicine, no surprise, is Daraxonrasib. ema.europa.eu/en/news/ema-fa…

EMA fast tracks review of a medicine for metastatic pancreatic cancer | European Medicines Agency...

Phased review has started to accelerate assessment of medicine with potential to address high unmet medical need

ema.europa.eu
1
10
1
47
5,250
Maximilian Reichert retweeted
Prisca Liberali@priscaliberaliJun 30
It is finally out 😍Check it out!! Multiscale integration of tissue and chromatin context converts cell heterogeneity into stable intestinal patterning: Cell cell.com/cell/fulltext/S0092… @CSchwayer @Silvia_Bar01 @d_brueckner @EdouardHannezo

Multiscale integration of tissue and chromatin context converts cell heterogeneity into stable...

During regeneration, tissues must translate transient cellular variability into stable spatial organization. Tissue architecture generates a density-dependent window of heterogeneity in the mechano...

cell.com
6
23
5
138
9,987
Maximilian Reichert retweeted
DKFZ@DKFZJul 1
Ein Team von Forschenden aus dem DKFZ & @hi_stem_lab hat einen neuen Ansatz zur Behandlung von fortgeschrittenem Darmkrebs entdeckt. Sie identifizierten einen Marker für metastasierten Darmkrebs, der die Achillesferse besonders aggressiver Tumorzellen ist. t1p.de/wzspb

Neu entdeckter Marker für metastasierten Darmkrebs ist die Achillesferse besonders aggressiver...

Ein Team unter Leitung von Forschenden aus dem Deutschen Krebsforschungszentrum (DKFZ) und dem Stammzell-Institut HI-STEM* hat einen vielversprechenden neuen Ansatz zur Behandlung von fortgeschritt...

dkfz.de
4
7
1,040
Maximilian Reichert retweeted
Hans Clevers@HansCleversJun 28
Organoid researchers!! Save the date for the annual "Organoids are Us"-symposium. Held at the Beatrix Theater in the center of beautiful historic Utrecht. Venue is a 20 minute train ride from Schiphol Airport Amsterdam. Program will follow shortly.
2
16
87
8,703
Maximilian Reichert retweeted
TU München@TU_MuenchenMay 22
The M1 #Munich #Medicine Alliance has launched the “Innovations for Patients” program, under which seven cross-institutional research projects will receive funding—five of them coordinated by researchers from our #university: go.tum.de/866191 #MedicalResearch 📷A. Koenig
4
11
1,247
Maximilian Reichert retweeted
Eric Topol
@EricTopolFeb 25
Tissue-specific basis for cancer evolution, as demonstrated with KRAS mutations nature.com/articles/s41586-0…
4
45
1
169
19,723
Maximilian Reichert retweeted
DKFZ@DKFZFeb 18
Researchers from the DKFZ, @hi_stem_lab and the biotech company Xilis have developed a new method for selecting the most effective drug for advanced colorectal cancer before treatment begins. The method is based on tiny 3D tumor models. t1p.de/c1gdx

3D microtumors could revolutionize treatment decisions

Chemotherapy is often a central component of treatment for advanced colorectal cancer. However, not every therapy is equally effective for every patient. Researchers from the German Cancer Research...

dkfz.de
3
10
694
Maximilian Reichert retweeted
Fabian Theis
@fabian_theisJan 8
🔬 pertpy: a unified, scalable framework for single-cell perturbation analysis, now out in Nature Methods Designed for modern perturbation data - CRISPR, drug screens, patient treatments - scaling to millions of cells and 1000s of conditions. 👉 nature.com/articles/s41592-0…
3
60
2
294
23,989
Maximilian Reichert retweeted
nature
@Nature19 Dec 2025
Nature research paper: Human assembloids recapitulate periportal liver tissue in vitro go.nature.com/3Y3f3fR

Human assembloids recapitulate periportal liver tissue in vitro

Nature - Hepatocyte organoids derived directly from human tissue enable long-term hepatocyte expansion and can be combined with portal mesenchyme and cholangiocyte organoids to form a...

nature.com
1
26
125
20,533
Maximilian Reichert retweeted
VomLaborInDiePraxis@DKTK_6 Oct 2025
Today at the #DKTK Community Meeting in Heidelberg: Researchers from all partner sites dive into Pillar 1 – Therapeutic Innovations. 🚀 Topics include functional precision oncology, high-throughput screening, immunotherapy, radio oncology & 3D models. #TranslationalCancerResearch
3
2
586
Maximilian Reichert retweeted
Grainne O'Kane
@graokane20 Sep 2025
PASS-01:ph II mFFX v GnP;#PDAC denovo met ds; excl gBRCA/PALB2 ➡️no clinically sig diff GnP v mFFX ➡️basal-like poor OS-mPFS on mFFX 3 mths ➡️54% receive 2nd line; mOS<6mths ➡️PDOs/ctDNA to come @AmberHabowski 1st-line biomarkers essential-RAS &🤞subtype doi.org/10.1200/JCO-25-00436
11
31
1,947
Load more